NCT01594216View on ClinicalTrials.gov

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

April 9, 2016

Conditions
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Interventions
DRUG

Ruxolitinib

DRUG

Exemestane

Trial Locations (1)

10104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01594216 - Ruxolitinib in Estrogen Receptor Positive Breast Cancer | Biotech Hunter | Biotech Hunter